Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

  title={Comparative manufacture and cell-based delivery of antiretroviral nanoformulations},
  author={Shantanu S Balkundi and Ari S. Nowacek and Ramya Veerubhotla and Han Chen and Andrea L. Martinez-Skinner and Upal Roy and Rodney Lee Mosley and Georgette D. Kanmogne and Xin-ming Liu and Alexander V. Kabanov and Tatiana K Bronich and JoEllyn McMillan and Howard E. Gendelman},
  journal={International Journal of Nanomedicine},
  pages={3393 - 3404}
Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were manufactured by wet milling, homogenization or sonication with a variety of excipients. The chemical, biological, immune, virological, and toxicological properties of these formulations were compared using an established monocyte-derived macrophage scoring indicator system. Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated differences amongst preparation methods… 

Figures and Tables from this paper

Development and characterization of a long-acting nanoformulated abacavir prodrug.

MABC synthesis and encasement in polymeric nanoformulations improved intracellular drug accumulation and demonstrate translational potential as part of a long-acting antiretroviral regimen.

A long acting nanoformulated lamivudine ProTide.

Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.

An overview of the application of nanomedicine to oral antiretroviral therapy is provided and how the current short-falls of this life-long therapy may be resolved using nanotechnology is outlined.

Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations

FA-nanoATV/r resulted in enhanced and sustained plasma and tissue ATV concentrations and was associated with transient local inflammation at the site of injection.

Creation of a long-acting nanoformulated dolutegravir

The authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.

Humanized Mice as a Platform for the Development of Long-Acting Nanoformulated Antiretroviral Therapy

Cell-carried nanoformulations of antiretroviral therapy (nanoART) were pioneered at the University of Nebraska Medical Center and targeting of the nanoART to monocyte-macrophages enabled “best” pharmacokinetic (PK) outcomes could lead to improved drug compliance, diminished viral resistance, and facilitation of virus reservoir reductions.

Cell-Based Drug Delivery for Improving Antiretroviral Therapeutic Outcomes

Target coating of the particles further facilitated pharmacokinetic and pharmacodynamics improvements over native or “naked uncoated” particle drug administrations, especially in reaching reservoirs of viral infection, such as the brain, gut, and lymphoid organs.

Development and characterisation of antiretroviral drugs encapsulated in polymer stabilised oil-in-water nanoemulsions

The aims of this thesis were to develop a novel nanoemulsion based formulation of EFV and LPV and to assess the suitability of this formulation as dosage form, and found that polymer stabilised oil-in-water nanoemulsions based on Castor oil have promising safety and pharmacological profiles.

Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

It is demonstrated that particle-cell interactions serve to enhance drug loading while facilitating drug tissue depots and transportation.



Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

It is posited that the repackaging of clinically available antiretroviral medications into nanoparticles for HIV-1 treatments may improve compliance and positively affect disease outcomes.

Cyclosporine A-Nanosuspension: Formulation, Characterization and In Vivo Comparison with a Marketed Formulation

In-vivo studies were carried out in albino rats and the pharmacokinetic parameters were compared with a marketed formulation, which indicated better results of the prepared formulation than the marketed one.

Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage

Detailed relationships between human monocyte and macrophage cytotoxicities and nanoART dose, size, surfactant, and preparation are investigated and underscore the potential importance of evaluating the physicochemical and functional properties of nanoART before human evaluations.

In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy.

Macrophage endocytic trafficking of antiretroviral nanoparticles.

Mechanisms of crystalline antiretroviral nanoparticle uptake, intracellular trafficking and release in human monocyte-derived macrophages are described, suggesting possible pathways of subcellular transport of antireTroviral nanoformulations that preserve both particle integrity and antirefiltration activities demonstrating the potential utility of this approach for targeted drug delivery.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

The results support the continued development of macrophage-mediated nanoART carriage for HIV-1 disease and show dose-dependent reduction in progeny virion production and HIV- 1 p24 antigen.

PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.

Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

AR drug concentrations from NPs are sustained for 28 days in vivo and anti-HIV inhibition was comparable to that of free drugs in vitro and could be a sustained treatment for delivery of AR drugs.

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

Results demonstrated AR NPs could be fabricated containing three antiretroviral drugs (RTV, LPV, EFV) and sustained release of AR from PLGA NP show high drug levels in PBMCs until day 28 without cytotoxicity.